FDA Seeks Standardization For NGS Tumor Testing
This article was originally published in The Gray Sheet
Without some standardization of cancer tumor tissue collection methods, sample enrichment, and synchronized sequencing criteria and platforms, next-generation sequencing tests could be of low quality for diagnoses, researchers cautioned at a recent FDA workshop. The agency is likely to develop a guidance to clarify best methods, an FDA official says.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.